Norwegian Adenomyosis Study III: Peristalsis

• Register: ClinicalTrials.gov
• Last refreshed on: 16 March 2021
• Main ID: NCT02197936
• Date of registration: 17/07/2014
• Prospective Registration: No
• Primary sponsor: Oslo University Hospital
• Public title: Norwegian Adenomyosis Study III: Peristalsis NAPPEDIII
• Scientific title: Norwegian Adenomyosis Study: Pathophysiology, Peristalsis, Expression Profiling and Diagnostics, Part III
• Date of first enrolment: July 2014
• Target sample size: 3
• Recruitment status: Terminated
• URL: https://clinicaltrials.gov/show/NCT02197936
• Study type: Observational

Countries of recruitment

Norway

Contacts

• Name: Tina Tellum, MD
• Affiliation: Oslo University Hospital, Ullevål

• Name: Marit Lieng, PhD, MD
• Affiliation: Oslo University Hospital

Key inclusion & exclusion criteria

Inclusion Criteria:

- Premenopausal women aged 20-45 years having been diagnosed with adenomyosis earlier
and have no other pathology of the uterus, regardless of clinical symptoms.

Exclusion Criteria:

- Postmenopausal women,

- Pregnant women,

- Gynaecological cancer,

- GnRH analog therapy or systemic hormone therapy in the last three months prior to
hysterectomy,

- Endometriosis,

- Uterine fibroids



Age minimum: 20 Years
Age maximum: 45 Years
Gender: Female

Health Condition(s) or Problem(s) studied

Dysmenorrhea

Adenomyosis

Infertility

Primary Outcome(s)

Altitude of peristaltic waves in mm [Time Frame: five minutes]

Frequency of peristaltic waves in Hz [Time Frame: five minutes]

Secondary Outcome(s)

direction of uterine peristalsis: antegrade, retrograde [Time Frame: 5 minutes, at time of ovulation]

Secondary ID(s)

2014/637c

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Helse Sor-Ost

Departement of Biomedical Engineering, Tel Aviv University, Tel Aviv, Israel

University of Oslo